EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Efficacy and Safety of HSK31679 in Asian Patients With MASLD: A Randomized Controlled Trial

Feng Xue, Wei Ma, Jixian Gao, Jinjun Chen, Wei Yue, Peili Bu, Qincong Chen, Hao Chen, Jianlong Sheng, Liang Chen, Fei Liu, Guangming Li und 20 weitere

Clinical Gastroenterology and Hepatology · 2026-04 · 24 (4) · 1068-1078

DOI: 10.1016/j.cgh.2025.08.009 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-04. Verfasst von Feng Xue und 31 weiteren Autor:innen. Beteiligte Einrichtung: Hepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital, Key Laboratory of Digital Intelligence Hepatology (Ministry of Education), School…. Hauptthemen laut MEDLINE: Fatty Liver. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Haisco Pharmaceutical Group.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: This study evaluated the efficacy and safety of the thyroid hormone receptor β agonist HSK31679 in Asian patients with metabolic dysfunction-associated steatotic liver disease (MASLD). METHODS: This was a phase 2a, multicenter, randomized, double-blind, placebo-controlled study at 26 centers in China. Subjects with a liver fat content (LFC) of ≥8% at screening, when assessed by magnetic resonance imaging-proton density fat fraction, were eligible. Subjects were randomly assigned in a 1:1:1:1:1 ratio using a centralized randomization system to receive daily oral HSK31679 40 mg, HSK31679 80 mg, HSK31679 160 mg, ezetimibe 10 mg, or placebo. The primary endpoint was a relative change from baseline in LFC after 12 weeks of treatment. RESULTS: A total of 210 participants were randomly assigned to placebo (n = 42), HSK31679 40 mg (n = 42), HSK31679 80 mg (n = 42), HSK31679 160 mg (n = 42), or ezetimibe (n = 42). At week 12, the mean relative change from baseline in LFC was -4.1% in the placebo group, -14.0% in the 40 mg group (mean difference vs placebo -9.9% [95% confidence interval (CI), -21.5% to 1.6%]; P = .092), -22.7% in the 80 mg group (-18.6% [95% CI, -30.2% to -7.0%]; P = .002), and -29.2% in the 160 mg group (-25.2% [95% CI, -36.8% to -13.5%]; P < .001). The most common treatment-emergent adverse event was diarrhea (11 [26.2%] of patients in the 40 mg group, 13 [31.0%] in the 80 mg group, 16 [38.1%] in the 160 mg group, and 2 [4.8%] in the placebo group). No drug-related serious adverse events or grade ≥3 adverse events were reported. CONCLUSIONS: In Asian MASLD patients, HSK31679 was well tolerated, with significant reductions in LFC after 12 weeks of treatment with 80 mg and 160 mg. CLINICALTRIALS: gov, Number: NCT05795517.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fatty LiverHumansMaleFemaleMiddle AgedDouble-Blind MethodTreatment OutcomeAdultChinaAsian PeoplePlacebosAgedDrug-Related Side Effects and Adverse ReactionsEzetimibeMagnetic Resonance Imaging

Stichwörter der Autor:innen

EfficacyHSK31679Metabolic Dysfunction–Associated Steatotic Liver DiseaseSafetyThyroid Hormone Receptor β Agonist

Substanzen

PlacebosEzetimibe

Autor:innen und Institutionen

  • Hepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital, Key Laboratory of Digital Intelligence Hepatology (Ministry of Education), School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing…
  • Department of Cardiology, Peking University First Hospital, Beijing, China.
  • Department of Cardiology, Cangzhou People's Hospital, Cangzhou, China.
  • Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Department of Infectious Disease, The First People's Hospital of Yunnan Province, Kunming, China.
  • Department of Cardiology, Qilu Hospital of Shandong University, Jinan, China.

Förderung

  • Haisco Pharmaceutical Group

Zitieren

APA

Xue, F., Ma, W., Gao, J., Chen, J., Yue, W., Bu, P., Chen, Q., Chen, H., Sheng, J., Chen, L., Liu, F., Li, G., Zhu, C., Zhong, B., Zhang, J., Cai, Q., Wang, L., Chen, Y., Pei, Z., …, & Wei, L. (2026). Efficacy and Safety of HSK31679 in Asian Patients With MASLD: A Randomized Controlled Trial. Clinical Gastroenterology and Hepatology, 24(4), 1068-1078. https://doi.org/10.1016/j.cgh.2025.08.009

Vancouver

Xue F, Ma W, Gao J, Chen J, Yue W, Bu P, et al. Efficacy and Safety of HSK31679 in Asian Patients With MASLD: A Randomized Controlled Trial. Clinical Gastroenterology and Hepatology. 2026;24(4):1068-1078. doi:10.1016/j.cgh.2025.08.009

BibTeX
@article{Xue2026,
  author = {Xue, Feng and Ma, Wei and Gao, Jixian and Chen, Jinjun and Yue, Wei and Bu, Peili and Chen, Qincong and Chen, Hao and Sheng, Jianlong and Chen, Liang and Liu, Fei and Li, Guangming and Zhu, Chuanwu and Zhong, Bihui and Zhang, Jianming and Cai, Qingxian and Wang, Le and Chen, Ying and Pei, Zhaohui and Yao, Lvfeng and Lv, Lingchun and Gao, Yanhang and Xia, Bihua and Ji, Xianyou and Liu, Yang and Du, Laijing and Ma, Genshan and Hao, Kunyan and Li, Fangqiong and Wu, Tingting and Huo, Yong and Wei, Lai},
  title = {Efficacy and Safety of HSK31679 in Asian Patients With MASLD: A Randomized Controlled Trial},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2026},
  volume = {24},
  number = {4},
  pages = {1068--1078},
  doi = {10.1016/j.cgh.2025.08.009}
}
Kostenlos starten →